Histological findings in chronic hepatitis C with autoimmune features
A J Czaja
Division of Gastroenterology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Search for more papers by this authorH A Carpenter
Division of Gastroenterology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Search for more papers by this authorA J Czaja
Division of Gastroenterology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Search for more papers by this authorH A Carpenter
Division of Gastroenterology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Search for more papers by this authorAbstract
To evaluate the histological findings in patients with chronic hepatitis C and autoimmune features, liver tissue specimens from 60 patients were graded under code for individual features and composite patterns that denoted autoimmune, viral, combined autoimmune and viral, and nondiscriminative changes. Portal, interface, and acinar hepatitis in any combination with plasma cell infiltration connoted an autoimmune pattern that was associated with higher serum levels of γ-globulin (2.4 ± 0.2 g/dL vs. 1.7 ± 0.1 g/dL; P = .0003) and immunoglobulin G (2,211 ± 227 mg/dL vs. 1,508 ± 83 mg/dL; P = .001) than patients with other patterns. Patients with the autoimmune pattern also had a greater frequency of cirrhosis (43% vs. 8%; P = .003), higher mean Knodell score (13.2 ± 0.9 vs. 6.8 ± 0.9; P < .0001), and a greater occurrence of high-titer smooth muscle antibodies (SMA) (13% vs. 0%; P = .05) than patients with other histological findings. HLA DR3 also occurred more frequently in these individuals than in other patients (48% vs. 15%; P = .01) and normal subjects (43% vs. 16%; P = .01). Patients with nondiscriminative patterns and interface hepatitis had clinical findings similar to those with autoimmune patterns, except for a lower mean serum level of γ-globulin. We conclude that the composite histological pattern that resembles autoimmune hepatitis is associated with greater immunoreactivity, inflammatory activity, and disease severity than other patterns. Interface hepatitis may be the most important histological finding associated with these clinical manifestations.
References
- 1 Tran A, Quaranta J–F, Benzaken S, Thiers V, Chau HT, Hastier P, Regnier D, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993; 18: 253–257.
- 2 Pawlotsky J–M, Yahia MB, Andre C, Voisin M–C, Intrator L, Roudot–Thoraval F, Deforges L, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case–control study. Hepatology 1994; 19: 841–848.
- 3 Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M, Bonkov–sky HL. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21: 613–619.
- 4 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Taswell HF, Homburger HA. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol 1993; 18: 342–352.
- 5 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology 1995; 108: 157–164.
- 6 Pawlotsky J–M, Roudot–Thoraval F, Simmonds P, Mellor J, Yahia M Ben, Andre C, Voisin M–C, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C serotypes. Ann Intern Med 1995; 122: 169–173.
- 7 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. DR human leukocyte antigens and disease severity in chronic hepatitis C. J Hepatol 1996; 24: 666–673.
- 8 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis. Dig Dis Sci 1995; 40: 2098–2106.
- 9 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol 1996; 24: 52–59.
- 10 Zein N, Persing D, Czaja AJ. Viral and genetic factors as determinants of autoimmune expression in chronic hepatitis C [Abstract]. Gastroenterology 1996; 110: A1176.
- 11 Czaja AJ. Extrahepatic immunologic features of chronic viral hepatitis. Dig Dis (in press).
- 12 Vento S, DiPerri G, Garofano T, Cosco L, Concia E, Ferraro T, Bassetti D. Hazards of interferon therapy for HBV–seronegative chronic hepatitis. Lancet 1989; 2: 926.
- 13 Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou J–P. Autoimmune chronic hepatitis exacerbated by alpha–interferon. Ann Intern Med 1992; 116: 51–53.
- 14 Shindo M, DiBisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992; 102: 1406–1408.
- 15 Farhat BA, Johnson PJ, Williams R. Hazards of interferon treatment in patients with autoimmune chronic active hepatitis [Letter]. J Hepatol 1994; 20: 560–561.
- 16 Garcia–Bury L, Garcia–Monzon C, Rodriguez S, Borque MJ, Garcia–San–chez A, Iglesias R, DeCastro M, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108: 1770–1777.
- 17 Fong T–L, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG. Short–term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 1994; 107: 196–199.
- 18 Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of autoimmune chronic hepatitis and chronic hepatitis C: favorable response to prednisone and azathioprine. Ann Intern Med 1995; 123: 32–34.
- 19 Czaja AJ, Magrin S, Fabiano C, Fiorentino G, Diquattro O, Craxi A, Pagliaro L. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci 1995; 40: 33–40.
- 20 Gonzalez–Peralta RP, Davis GL, Lau JYN. Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. J Hepatol 1994; 21: 255–259.
- 21 Hino K, Okuda M, Konishi T, Yamashita A, Kayano K, Kubota M, Yasunaga M, et al. Analysis of lymphoid follicles in liver of patients with chronic hepatitis C. Liver 1992; 12: 387–391.
- 22 Mosnier J–F, Degott C, Marcellin P, Henin D, Erlinger S, Benhamou J–P. The intraportal lymphoid nodule and its environment in chronic active hepatitis C: an immunohistochemical study. Hepatology 1993; 17: 366–371.
- 23 Mosnier J–F, Scoazec J–Y, Marcellin P, Degott C, Benhamou J–P, Feld–mann G. Expression of cytokine–dependent immune adhesion molecules by hepatocytes and bile duct cells in chronic hepatitis C. Gastroen–terology 1994; 107: 1457–1468.
- 24 Minutello MA, Pileri P, Unutmaz D, Censini S, Kuo G, Houghton M, Brunette MR, et al. Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C. J Exp Med 1993; 178: 17–25.
- 25 Miller RH, Purcell RH. Hepatitis C virus shares amino acid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus subgroups. Proc Natl Acad Sci U S A 1990; 87: 2057–2061.
- 26 Dienes HP, Popper H, Arnold W, Lobeck H. Histological observations in human hepatitis non–A, non–B hepatitis. Hepatology 1982; 2: 552–571.
- 27 Hiramatsu N, Hayashi N, Haruna Y, Kasahara A, Fusamoto H, Mori C, Fuke I, et al. Immunohistochemical detection of hepatitis C virus–infected hepatocytes in chronic liver disease with monoclonal antibodies to core, envelope and NS3 regions of the hepatitis C virus genome. Hepatology 1992; 16: 306–311.
- 28 Shindo M, Di Besceglie AM, Hoofnagle JH. Long–term follow–up of patients with chronic hepatitis C treated with alfa–interferon. Hepatology 1992; 15: 1013–1016.
- 29 Romeo R, Pol S, Berthelot P, Brechot C. Eradication of hepatitis C virus RNA after alpha–interferon therapy. Ann Intern Med 1994; 121: 276–277.
- 30 Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824–1832.
- 31 Johnson PJ, McFarlane IG, Alvarez F, Bianchi FB, Bianchi L, Burroughs A, Chapman RW, et al. Meeting Report. International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998–1005.
- 32 Czaja AJ, Carpenter HA. Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci 1996; 41: 305–314.
- 33 Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24: 1068–1073.
- 34 Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 1290–1295.
- 35 Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–435.
- 36 Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513–1520.
- 37 Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histologic grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696–699.
- 38 Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15: 572–577.
- 39 Scheuer PJ, Ashrafzadeh P, Sherlock S, Brown D, Dusheiko GM. The pathology of hepatitis C. Hepatology 1992; 15: 567–571.
- 40 Czaja AJ. Autoimmune hepatitis and viral infection. Gastroenterol Clin North Am 1994; 23: 547–566.
- 41 Czaja AJ, Strettel MDJ, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, Williams R. Associations between alleles of the major histocompati–bility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 317–323.
- 42 Czaja AJ. Autoimmune chronic active hepatitis–a specific entity? The negative argument J Gastroenterol Hepatol 1990; 5: 343–351.
- 43 Czaja AJ. Autoantibodies. Baillieres Clin Gastroenterol 1995; 9: 723–744.
- 44 Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1–B8–DR3 are independent risk factors. Hepatology 1991; 13: 701–706.
- 45 Sanchez–Urdazpal L, Czaja AJ, van Hoek B, Krom RAF, Wiesner RH. Prognostic features and role of liver transplantation in severe corticoste–roid–treated autoimmune chronic active hepatitis. Hepatology 1992; 15: 215–221.
- 46 Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993; 105: 1502–1507.
- 47 Doherty DG, Donaldson PT, Underbill JA, Farrant JM, Duthie A, Mieli–Vergani G, McFarlane IG, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994; 19: 609–615.
- 48 Czaja AJ. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci 1995; 40: 435–456.
- 49 Saracco G, Touscoz A, Durazzo M, Rosina F, Donegani E, Chiandussi L, Gallo V, et al. Antibodies and response to alpha–interferon in patients with chronic viral hepatitis. J Hepatol 1990; 11: 339–343.
- 50 Pagliaro L, Craxi A, Cammaa C, Tine F, DiMarco V, Lo lacono O, Almasio P. Interferon–alfa for chronic hepatitis C: an analysis of pre–treatment clinical predictors of response. Hepatology 1994; 19: 820–828.